ASCO 2020：11项中国研究成果入选口头报告，17项Poster报告

受全球新冠疫情影响，原定于5月初29日~6月初2日在费城举行的美国政府流行病学学都会（ASCO）年都会上周将首次以直通上形式举办，这是目前最大规模的直通上盛都会。今天，代表大都会的内容可题目公布，一共103个sessions，里国一共有11项研究者入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或罗德里格斯替尼加卡培他浜用以HER2+移到性乳腺食道癌（PHOEBE）：一项III期随机试验性。

首站：移到性乳腺食道癌

写作者：里国医学科学院公立医院徐兵河名誉教授、马飞名誉教授，浙江大学附属公立医院胡夕春名誉教授等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性乳腺食道癌标准用药后卡培他浜维持节拍化疗的III期试验性（SYSUCC-001）。

首站：乳腺食道癌—渐进/区域/辅助用药

写作者：里山大学公一共卫生里心王树森名誉教授等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用移到性大脑的表型特征来预报大脑脊液里反向DNA探测的机率: 新来进行反抗外公赢

首站：新来进行解决问题外公问题

写作者：李美芹 李德兰等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对里拉拉非尼作为后期肝蛋白质食道癌的主力用药：一项全站字句、随机、多里心II/III期试验性。

首站：中枢神经食道癌—食道静脉、十二指肠和肝胆

写作者：四川大学亚东公立医院毕锋名誉教授、里国外公百姓解放军八一公立医院秦叔逵名誉教授等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里国后期肝食道癌病人阿帕替尼西段用药：一项随机、CPA相异、双盲III期研究者

首站：中枢神经食道癌—食道静脉、十二指肠和肝胆

写作者：里国外公百姓解放军八一公立医院秦叔逵名誉教授、四川大学亚东公立医院李秋名誉教授等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

后期高血压卵巢食道癌二次蛋白质减灭术的一项随机III期试验性：SOC1 / SGOG-OV2。

不定期：妇产科食道乳癌

写作者：浙江大学附属里山公立医院臧荣余名誉教授等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈食道癌根治性卵巢输卵管后辅助用药里的序贯放化疗对比除此以外前列腺癌或该系统放化疗（STARS研究者）：一项随机、相异、全站字句的III期试验性。

代表大都会：妇产科食道乳癌

写作者：里山大学公一共卫生里心黄鹤名誉教授、刘继红名誉教授等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：辅助吉非替尼对比化疗用以可切除的EGFR突变的N1-N2期NSCLC-随机III期流行病学试验性的事与愿违总体一共存系统性。

不定期：心肌梗塞—非小蛋白质渐进-区域/小蛋白质/其他胸部

写作者：广东省外公百姓公立医院吴一龙名誉教授等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR突变寡移到非小蛋白质心肌梗塞病人主力赖氨酸还原酶抑制剂合组或不合组积极前直通渐进前列腺癌：III期全站字句流行病学随机试验性（SINDAS）的里期结果（NCT02893332）。

不定期：心肌梗塞-非小蛋白质移到

写作者：四川省外公百姓公立医院曾铭名誉教授等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序性死亡-1（PD-1）的人源化IgG4单克隆抗体合组阿昔替尼用以移到性表皮卵巢癌病人的Ib期研究者的总一共存期和生物标志物系统性。

不定期：卵巢癌/皮肤食道癌

写作者：华东师范大学公立医院郭军、盛锡楠名誉教授等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：统一标准CAR-T蛋白质首次人体试验性用药复发/难治性T蛋白质急性淋巴蛋白质白血病（r/r T-ALL）的实用性和。代表大都会：开发里的用药新科技-免疫用药。写作者：王欣欣等内容可：3013宣传品：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在后期静脉粒状蛋白质食道癌病人里的应用以：一项随机的全站字句II期试验性（ORIENT-2）。代表大都会：中枢神经食道癌-食道静脉食道癌、十二指肠食道癌和肝胆道食道癌写作者：徐建明名誉教授等内容可：4511宣传品：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T蛋白质对髓母蛋白质瘤的根治性用药代表大都会：里枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东内容可：2522宣传品。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在后期错配修复缺陷病人里的应用以代表大都会：开发里的用药学-免疫用药写作者：沈琳名誉教授等内容可：3021宣传品。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART用药复发/难治性ACUTE淋巴蛋白质白血病/淋巴瘤的唯一未人体流行病学试验性代表大都会: 开发性用药学-免疫用药写作者简介：张明志，杨林等内容可：3026宣传品: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 昂替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）合组使用后期实体瘤病人的Ib期研究者代表大都会：发展性用药学---分子都会靶向药物和微生物学写作者：龚继芳，沈琳名誉教授等内容可：3523宣传品：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin合组紫杉醇和nedaplatin用药高血压或移到性静脉粒状蛋白质食道癌（ESCC）病人的II期研究者。代表大都会：中枢神经食道癌-食道静脉、十二指肠和肝胆道食道癌的研究者写作者：王志强于，李玉红，王德申，王凤华，任超，谭琼 王志强于、李玉红、王德深、王凤华、任超、谭琼内容可：4522宣传品：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大都会：中枢神经食道癌-食道静脉食道癌、十二指肠食道癌和肝胆管食道癌的西段用药写作者：宋艳等内容可：4524宣传品：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种唾液外体放射状RNA分类器用以初始活检时探测高等级食道癌的唾液外体放射状RNA分类器：一项多里心的回顾性研究者代表大都会：脊柱生殖系统食道乳癌----食道癌、睾丸食道癌和食道癌写作者简介：Liaoyuan Li等内容可：5522宣传品。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 渐进后期宫颈食道癌比方说化疗后的辅助化疗代表大都会: 妇产科食道乳癌写作者简介： 李珉珉等内容可：6031宣传品：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼用药甲状腺髓性食道癌的相关性：基于ALTER01031试验性的系统性。都会话：躯干写作者：天津市外公百姓政府公立医院擅长于名誉教授内容可：6526宣传品。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和年龄对安洛替尼用药后病人结局的影响: ALTER01031的亚组系统性代表大都会：躯干写作者：天津市外公百姓政府公立医院擅长于名誉教授内容可：6527宣传品。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA系统性预报I-IIIA期非小蛋白质心肌梗塞（NSCLC）病人术后复发: GASTO1035和GASTO1018的结果代表大都会：心肌梗塞-非小蛋白质渐进-区域性/小蛋白质/小蛋白质/其他胸科食道乳癌写作者：Si-Yu Wang等内容可：9023宣传品：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白质心肌梗塞（NSCLC）里EGFR赖氨酸还原酶抑制剂的新型耐药机制代表大都会:心肌梗塞-非小蛋白质移到性心肌梗塞写作者简介：赵昕，金玲玲，满宇，欧秋香，和黄，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧秋香、和黄、薛武、杨绍、范敏内容可：9528宣传品：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验性里后期卵巢癌总一共存的替代终点代表大都会：卵巢癌/皮肤食道癌写作者：聂润聪，袁书强于，李元芳，陈英波，周志伟 聂润聪、袁书强于、李元芳、陈英波、周志伟内容可：10030宣传品：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼用药复发或移到性病症恶性骨病人的II期研究者代表大都会： 恶性肿瘤写作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525宣传品。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 近期评价安罗替尼在后期恶性肿瘤病人多直通用药里的实用性和。代表大都会：恶性肿瘤写作者：姚伟涛，陈家强于，张鹏，王欣，杜新辉，田志浩，牛晓颖 姚伟涛、陈家强于、张鹏、王鑫、杜鑫辉、田志超、牛晓英内容可：11526宣传品：414